RGC Description — Regencell Bioscience Holdings Ltd

Regencell Bioscience is a holding company. Through its subsidiaries, Co. is an early-stage bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder, and infectious diseases affecting people's immune system such as COVID.

Company Name: 
Regencell Bioscience Holdings Ltd
Drugs & Pharmaceuticals
Number of ETFs Holding RGC: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   RGC Weight   RGC Amount 
 DIV   3.78%   $8,876,433         
Quotes delayed 20 minutes

Email EnvelopeFree RGC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Hold (2.17 out of 4)
76th percentile
(ranked higher than approx. 76% of all stocks covered)

Analysts Forecast:
RGC Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding RGC | Regencell Bioscience Holdings Ltd | ETF Channel |

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.